Heart rate is a fundamental determinant of cardiac oxygen consumption and plays a pivotal role in the pathophysiology of chronic stable angina (CSA). Ivabradine selectively and specifically inhibits the sino-atrial If current, slowing selectively heart rate without other significant haemodynamic effects. The consequent clinical effects are a sinus rate reduction similar to that obtained with beta-blockers, but without the related haemodynamic side effects.
Ivabradine clinical benefits have been demonstrated both in patients with stable coronary artery disease (CAD) with associated systolic left ventricular dysfunction or in patients with congestive heart failure (HF). In this review we focused on the pharmacology and clinical research about ivabradine in the context of anti-ischemic therapy for CAD patients. Actually most guidelines suggest ivabradine therapy as last resort antianginal drugs in patients with uncontrolled symptoms or excessive heart rate despite maximum tolerated beta-blockade. However, the peculiar pharmacologic effects of the drug suggest that most patients with CAD might benefit from adding ivabradine to their therapeutic schemata. In fact, even if the recently released main analysis of the SIGNIFY study seems not to support an employ of ivabradine in primary prevention, it is easy to imagine a future wider use of this drug in elderly patients with incomplete myocardial revascularization and in patients with total chronic coronary occlusions and failure or unacceptable risk for percutaneous or surgical coronary revascularization.
Keywords: Angina pectoris, coronary artery disease, ivabradine, left ventricular ejection fraction, percutaneous coronary intervention.
Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Ivabradine: a Selective If Current Inhibitor in the Treatment of Stable Angina
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction
Current Cardiology Reviews Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Preoperative Levosimendan. A New Way for Organoprotection
Current Pharmaceutical Design Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology